Inventiva’s (IVA) “Buy” Rating Reiterated at UBS Group

UBS Group reissued their buy rating on shares of Inventiva (NASDAQ:IVA) in a research report sent to investors on Wednesday, MarketBeat.com reports. UBS Group currently has a $12.00 price target on the stock, up from their prior price target of $3.00.

A number of other research analysts have also recently weighed in on IVA. Wall Street Zen upgraded Inventiva to a “hold” rating in a research report on Saturday, October 18th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Inventiva in a report on Tuesday, September 30th. Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. HC Wainwright raised their price objective on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Finally, Guggenheim cut their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.57.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $4.83 on Wednesday. The business’s 50 day simple moving average is $4.32 and its 200-day simple moving average is $4.46. Inventiva has a 12 month low of $2.11 and a 12 month high of $7.98.

Institutional Trading of Inventiva

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Inventiva in the 3rd quarter worth approximately $649,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter valued at $116,000. Finally, Creative Planning acquired a new position in Inventiva in the second quarter valued at $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.